In Med Pharmaceuticals, Inc (Imlff) Signs R&D Agreement With Atera

InMed Signs R&D Agreement with ATERA

InMed Pharmaceuticals, Inc.(“InMed” or the “Company”) (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce it has entered into a research and development collaboration with ATERA SAS of France , a leading tissue engineering company specializing in the development of advanced human tissue models.

Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (‘EB’) to evaluate the in vitro drug efficacy of InMed’s lead compound, INM-750, a proprietary, topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. ATERA will also investigate the beneficial effects oftopically applied INM-750at ultra-structural cellular and molecular levelsonin vitro 3D reconstructed human full thickness (dermis-epidermis) skin models composed of...



See Article on Marijuana Stocks HERE